Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Remedy: Strong Cash flows from Development Fees

TO

VL

Tomas Otterbeck

Viktor Lindström

2022-05-13

08:34

Redeye comments on Remedy’s Q1 business review. Revenue was EUR 1.3 million above our estimate, EUR 12.7 million versus EUR 11.4 million. The cost base was roughly in line, which resulted in an EBIT somewhat above our estimate.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers